Arbutus Biopharma (ABUS) EBITDA Margin (2013 - 2026)
Arbutus Biopharma (ABUS) posted EBITDA Margin of 94.3% for Q1 2026, up 118.73% sequentially from 503.33% in Q4 2025, and up 155116.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
Arbutus Biopharma (ABUS) EBITDA Margin (2013 - 2026) Analysis & Trends
Arbutus Biopharma has reported EBITDA Margin for 14 years, with the latest figure at 94.3% in Q1 2026.
- Quarterly EBITDA Margin rose 155116.0% year-over-year to 94.3% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 81.72% (up 137260.0% YoY) and the FY2025 annual result came in at 270.96%, up 96577.0% from the prior year.
- EBITDA Margin grew to 94.3% in Q1 2026 per ABUS's latest filing, from 503.33% in the prior quarter.
- Over five years, EBITDA Margin peaked at 94.3% in Q1 2026 and troughed at 1636.86% in Q3 2025.
- A 5-year average of 671.9% and a median of 462.82% in 2023 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2024 and 2026: EBITDA Margin slumped 113838 bps in 2024, then jumped 155116 bps in 2026.
- Over 5 years, EBITDA Margin stood at 361.28% in 2022, then slumped by 168 bps to 967.23% in 2023, then climbed by 8 bps to 885.2% in 2024, then surged by 43 bps to 503.33% in 2025, then soared by 119 bps to 94.3% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 94.3%, 503.33%, and 1636.86% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Arbutus Biopharma | 1.02 Bn | 927.31 Mn | - | -588.17% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -588.17% |
| Mar 31, 2026 | 94.30% |
| Dec 31, 2025 | -503.33% |
| Sep 30, 2025 | -1,636.86% |
| Jun 30, 2025 | 13.86% |
| Mar 31, 2025 | -1,456.86% |
| Dec 31, 2024 | -885.20% |
| Sep 30, 2024 | -1,601.19% |
| Jun 30, 2024 | -1,250.46% |
| Mar 31, 2024 | -1,263.90% |
| Dec 31, 2023 | -967.23% |
| Sep 30, 2023 | -462.82% |
| Jun 30, 2023 | -395.29% |
| Mar 31, 2023 | -260.40% |
| Dec 31, 2022 | -361.28% |
| Sep 30, 2022 | -299.24% |
| Jun 30, 2022 | -99.07% |
| Mar 31, 2022 | -87.23% |
| Dec 31, 2021 | -648.66% |
| Sep 30, 2021 | -537.75% |